Wyeth Cordarone I.V.
Executive Summary
Wyeth will ask FDA to reconsider its decision to deny pediatric exclusivity for the antiarrhythmic Cordarone I.V. FDA concluded that the company had provided "insufficient documentation to meet the provisions of the agency's request." Wyeth conducted a 61-patient study in 27 centers in the U.S. and five other countries. Half the patients were from the U.S. Cordarone I.V (amiodarone) was approved in August 1995 under orphan drug status; six months of pediatric exclusivity would have extended protection to Feb. 3, 2003...
You may also be interested in...
Wyeth Cordarone I.V. (correction)
Wyeth will ask FDA to amend Cordarone I.V. (amidarone) labeling to include safety data from a 61-patient trial used to request pediatric exclusivity for the antiarrhythmic. Labeling currently states that the safety and efficacy in the pediatric patients has not been established and references reports of fatal "gasping" syndrome in neonates associated with the preservative benzyl alcohol. FDA denied Wyeth six months of pediatric exclusivity citing "insufficient documentation"; the company does not believe it has recourse to appeal. "The Pink Sheet" (1Oct. 21, In Brief) incorrectly stated that Wyeth would ask FDA to reconsider its decision...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.